HMGN5 is a member of the high mobility group nucleosome binding domain (HMGN) protein family. HMGN proteins are ubiquitously expressed in vertebrate cells. They are nuclear proteins that bind specifically to nucleosomes without specificity for the DNA sequence and affect the structure and function of chromatin. HMGN5 sequences have been detected in all vertebrate tissues examines. HMGN5 differs from the other members of the HMGN family in that it is significantly larger and its amino acid sequence varies significantly between different vertebrate species

Bustin, Michael

Furusawa, Takashi

Atlas of Genetics and Cytogenetics in Oncology and Haematology

I-Revues

Gene Section 
Short Communication 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(1) 3 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
HMGN5 (High Mobility Group Nucleosome 
binding domain 5) 
Michael Bustin, Takashi Furusawa 
National Cancer Institute, NIH, Building 37, Room 3122, 37 Convent Drive, Bethesa, MD 20892, US. 
bustinm@mail.nih.gov; furusawt@mail.nih.gov; http://irp.nih.gov/pi/michael-bustin 
Published in Atlas Database: April 2016 
Online updated version : http://AtlasGeneticsOncology.org/Genes/HMGN5ID52454chXq21.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/68126/04-2016-HMGN5ID52454chXq21.pdf 
DOI: 10.4267/2042/68126
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
HMGN5 is a member of the high mobility group 
nucleosome binding domain (HMGN) protein 
family. HMGN proteins are ubiquitously expressed 
in vertebrate cells. They are nuclear proteins that 
bind specifically to nucleosomes without specificity 
for the DNA sequence and affect the structure and 
function of chromatin. HMGN5 sequences have 
been detected in all vertebrate tissues examines. 
HMGN5 differs from the other members of the 
HMGN family in that it is significantly larger and its 
amino acid sequence varies significantly between 
different vertebrate species. 
Keywords: HMGN5, NSBP1, Chromatin 
Identity 
Other names: NSBP1, NBP-45 
HGNC (Hugo): HMGN5 
Location (base pair): Starts at 81113701 and ends 
at 81201942 bp from pter (according to NCBI 11-
Apr_2016) 
Reproduced from: HMGN5/NSBP1: a new member of the HMGN protein family that affects chromatin structure and function. 
Rochman M, Malicet C, Bustin M. Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):86-92. doi: 0.1016/j.bbagrm.2009.09.012. 
Review. PMID: 20123071
HMGN5 (High Mobility Group Nucleosome binding domain 5) Bustin M and Furusawa T 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(1) 4 
 
 
Organization of the human HMGN5 and mouse Hmgn5 gene. Exons are marked by red blocks and untranslated regions are 
marked by white boxes. The number of amino acids encoded by each exon is indicated. Reproduced from: HMGN5/NSBP1: a 
new member of the HMGN protein family that affects chromatin structure and function. Rochman M, Malicet C, Bustin M. 
Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):86-92. doi: 0.1016/j.bbagrm.2009.09.012. Review. PMID: 20123071 
 
 
DNA/RNA 
Description 
NCBI Reference Sequence: NC_000023.11; Coding 
positions from 81,113,701 to 81,201,942 (length: 
88,242 bp). Both human and mouse Hmgn5 genes 
are composed of 6 exons and 5 introns. 
Transcription 
849 bp cDNA for Human HMGN5. No splicing 
isoforms are reported as of April 2016. 
Protein 
Description 
Reference sequence for HMGN5 protein: 
NP_110390.1. HMGN5 contains 282 amino acid  
residues with a molecular weight of 31525 Da. 
HMGN5 belongs to the HMGN protein family. 
HMGN5 contains a Nucleosome Bingding Domain 
(residue 12-36) for chromatin interaction. 
Expression 
Expressed at low levels in most vertebrate cells. 
Localisation 
Nucleus. 
Function 
Modulates chromatin structure. 
Homology 
HomoloGene (NCBI) Genes identified as putative 
homologs: NP_110390.1 HMGN5, Homo sapiens; 
XP_001144951.2 Hmgn5, Pan troglodytes; 
XP_001103630 Hmgn5 Macaca mulatta; 
XP_002699982.3 Hmgn5, Bos taurus. 
 
 
Schematic representation of structural domains of mouse and human HMGN5 proteins. Localization of each domain is related to 
the amino acid sequences of the proteins numbered on top of each scheme. Reproduced from: HMGN5/NSBP1: a new member 
of the HMGN protein family that affects chromatin structure and function. Rochman M, Malicet C, Bustin M. Biochim Biophys 
Acta. 2010 Jan-Feb;1799(1-2):86-92. doi: 0.1016/j.bbagrm.2009.09.012. Review. PMID: 20123071 
HMGN5 (High Mobility Group Nucleosome binding domain 5) Bustin M and Furusawa T 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(1) 5 
 
Implicated in 
Clear cell renal cell carcinoma 
(ccRCC) 
HMGN5 expression is detected in renal tissues from 
clear cell renal cell carcinoma (ccRCC) patients and 
in ccRCC cell lines, and its expression level is 
associated with tumor grade.  
Knockdown of HMGN5 induced cell cycle arrest 
and apoptosis, and inhibited invasion in ccRCC cell 
line 786-O. (Ji et al, 2012). 
Prostate Cancer 
Knock down of HMGN5 inhibits the in vitro and in 
vivo growth of the human prostate cancer cell line 
DU145 by inducing cell cycle arrest and apoptosis 
(Jiang et al, 2010). Similar effect is also observed in 
the LNCaP prostate cancer cell line, too (Zhang et al, 
2012).  
HMGN5 knockdown exhibit increased apoptosis 
rate in response to ionizing radiation (Su et al, 2015). 
The normal prostate epithelial cells which are 
induced Ectopic HMGN5 expression results in 
oncogenic phenotype such as colony formation and 
invasion (Guo et al, 2015).  
Tumorigenic activity of the cells which overexpress 
HMGN5 is suppressed by MIR340 (microRNA-340) 
(Wei et al, 2015). 
Gliomas 
HMGN5 is highly expressed in both low-grade and 
high-grade glioma tissue samples than normal brain 
tissues.  
The down regulation of HMGN5 expression in 
human glioma cell line (U251 and U87) caused cell 
cycle arrest and apoptosis. (Qu et al, 2011). 
Bladder cancer 
The protein level of HMGN5 in surgically removed 
bladder cancer specimens and human bladder cell 
lines is correlated with the increased tumor grade and 
pathologic stage.  
Knock down of HMGN5 reduced cell viability and 
cell cycle promotion (Wahafu et al, 2010; Gan et al, 
2015).  
The expression level of HMGN5 is suppressed by 
MIR186 in human bladder cancer cells (Yao et al, 
2015). 
Lung cancer 
HMGN5 is highly expressed in lung cancer cell lines 
A549 and H1299. Downregulation of HMGN5 
inhibits cell proliferation and colony formation 
(Chen et al, 2012).  
MIR326 downregulated HMGN5 expression in the 
non-small cell lung cancer (NSCLC) cell and 
inhibited cell proliferation and invasion of NSCLC 
(Li et al, 2016). 
Osteosarcoma 
Both HMGN5 RNA and HMGN5 protein are highly 
expressed in human osteosarcoma tumor. The 
expression level is also upregulated in osteosarcoma 
cell lines SaO2 and HOS while other cell lines U-
2OS and MG63 showed lower expression level. 
HMGN5 expression is induced by anticancer agents 
in these cell lines. Overexpression of HMGN5 in U-
2OS and MG63 cells increased drug resistance by 
upregulating autophagy (Yang et al, 2014). 
Breast cancer 
HMGN5 is highly expressed in breast cancer tissues 
when compared with the adjacent non-cancerous 
tissues. Clinical and histopathologic analysis 
revealed that HMGN5 expression level is correlated 
to the tumor grade and staging. Using the human 
breast cancer cell line MCA-MB-213 as a model, 
HMGN5 knockdown resulted in inhibition of 
migration and invasion, and induced cell death 
(Weng et al, 2015). 
References 
Chen P, Wang XL, Ma ZS, Xu Z, Jia B, Ren J, Hu YX, Zhang 
QH, Ma TG, Yan BD, Yan QZ, Li YL, Li Z, Yu JY, Gao R, 
Fan N, Li B, Yang JL. Knockdown of HMGN5 expression by 
RNA interference induces cell cycle arrest in human lung 
cancer cells. Asian Pac J Cancer Prev. 2012;13(7):3223-8 
Ciappio ED, Krausz KW, Rochman M, Furusawa T, Bonzo 
JA, Tessarollo L, Gonzalez FJ, Bustin M. Metabolomics 
reveals a role for the chromatin-binding protein HMGN5 in 
glutathione metabolism. PLoS One. 2014;9(1):e84583 
Furusawa T, Rochman M, Taher L, Dimitriadis EK, 
Nagashima K, Anderson S, Bustin M. Chromatin 
decompaction by the nucleosomal binding protein HMGN5 
impairs nuclear sturdiness. Nat Commun. 2015 Jan 
22;6:6138 
Gan Y, Tan J, Yang J, Zhou Y, Dai Y, He L, Yao K, Tang Y. 
Knockdown of HMGN5 suppresses the viability and 
invasion of human urothelial bladder cancer 5637 cells in 
vitro and in vivo. Med Oncol. 2015 Apr;32(4):136 
Gerlitz G. HMGNs, DNA repair and cancer. Biochim 
Biophys Acta. 2010 Jan-Feb;1799(1-2):80-5 
González-Romero R, Eirín-López JM, Ausió J. Evolution of 
high mobility group nucleosome-binding proteins and its 
implications for vertebrate chromatin specialization. Mol Biol 
Evol. 2015 Jan;32(1):121-31 
Guo Z, Zhang X, Li X, Xie F, Su B, Zhang M, Zhou L. 
Expression of oncogenic HMGN5 increases the sensitivity 
of prostate cancer cells to gemcitabine. Oncol Rep. 2015 
Mar;33(3):1519-25 
He J, Liu C, Wang B, Li N, Zuo G, Gao D. HMGN5 blockade 
by siRNA enhances apoptosis, suppresses invasion and 
increases chemosensitivity to temozolomide in 
meningiomas. Int J Oncol. 2015 Oct;47(4):1503-11 
Huang C, Zhou LQ, Song G. [Effect of nucleosomal binding 
protein 1 in androgen-independent prostatic carcinoma]. 
Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):657-60 
Ji SQ, Yao L, Zhang XY, Li XS, Zhou LQ. Knockdown of the 
nucleosome binding protein 1 inhibits the growth and 
HMGN5 (High Mobility Group Nucleosome binding domain 5) Bustin M and Furusawa T 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(1) 6 
 
invasion of clear cell renal cell carcinoma cells in vitro and 
in vivo. J Exp Clin Cancer Res. 2012 Mar 15;31:22 
Jiang N, Zhou LQ, Zhang XY. Downregulation of the 
nucleosome-binding protein 1 (NSBP1) gene can inhibit the 
in vitro and in vivo proliferation of prostate cancer cells. 
Asian J Androl. 2010 Sep;12(5):709-17 
King LM, Francomano CA. Characterization of a human 
gene encoding nucleosomal binding protein NSBP1. 
Genomics. 2001 Jan 15;71(2):163-73 
Kugler JE, Horsch M, Huang D, Furusawa T, Rochman M, 
Garrett L, Becker L, Bohla A, Hölter SM, Prehn C, Rathkolb 
B, Racz I, Aguilar-Pimentel JA, Adler T, Adamski J, Beckers 
J, Busch DH, Eickelberg O, Klopstock T, Ollert M, Stöger T, 
Wolf E, Wurst W, Yildirim AÖ, Zimmer A, Gailus-Durner V, 
Fuchs H, Hrabě de Angelis M, Garfinkel B, Orly J, 
Ovcharenko I, Bustin M. High mobility group N proteins 
modulate the fidelity of the cellular transcriptional profile in 
a tissue- and variant-specific manner. J Biol Chem. 2013 
Jun 7;288(23):16690-703 
Li D, Du X, Liu A, Li P. Suppression of nucleosome-binding 
protein 1 by miR-326 impedes cell proliferation and invasion 
in non-small cell lung cancer cells. Oncol Rep. 2016 
Feb;35(2):1117-24 
Malicet C, Rochman M, Postnikov Y, Bustin M. Distinct 
properties of human HMGN5 reveal a rapidly evolving but 
functionally conserved nucleosome binding protein. Mol 
Cell Biol. 2011 Jul;31(13):2742-55 
Moretti F, Rolando C, Winker M, Ivanek R, Rodriguez J, Von 
Kriegsheim A, Taylor V, Bustin M, Pertz O. Growth Cone 
Localization of the mRNA Encoding the Chromatin 
Regulator HMGN5 Modulates Neurite Outgrowth. Mol Cell 
Biol. 2015 Jun 1;35(11):2035-50 
Qu J, Yan R, Chen J, Xu T, Zhou J, Wang M, Chen C, Yan 
Y, Lu Y. HMGN5: a potential oncogene in gliomas. J 
Neurooncol. 2011 Sep;104(3):729-36 
Rochman M, Malicet C, Bustin M. HMGN5/NSBP1: a new 
member of the HMGN protein  family that affects chromatin 
structure and function Biochim Biophys Acta  2010  Jan-
Feb;1799(1-2):86-92 
Rochman M, Postnikov Y, Correll S, Malicet C, Wincovitch 
S, Karpova TS, McNally JG, Wu X, Bubunenko NA, 
Grigoryev S, Bustin M. The interaction of NSBP1/HMGN5 
with nucleosomes in euchromatin counteracts linker 
histone-mediated chromatin compaction and modulates 
transcription Mol Cell  2009 Sep 11;35(5):642-56 
Shirakawa H, Landsman D, Postnikov YV, Bustin M. NBP-
45, a novel nucleosomal binding protein with a tissue-
specific and developmentally regulated expression J Biol 
Chem  2000 Mar 3;275(9):6368-74 
Su B, Shi B, Tang Y, Guo Z, Yu X, He X, Li X, Gao X, Zhou 
L. HMGN5 knockdown sensitizes prostate cancer cells to 
ionizing radiation Prostate  2015 Jan;75(1):33-44 
Tang WY, Morey LM, Cheung YY, Birch L, Prins GS, Ho 
SM. Neonatal exposure to estradiol/bisphenol A alters 
promoter methylation and expression of Nsbp1 and Hpcal1 
genes and transcriptional programs of Dnmt3a/b and 
Mbd2/4 in the rat prostate gland throughout life 
Endocrinology  2012 Jan;153(1):42-55 
Tang WY, Newbold R, Mardilovich K, Jefferson W, Cheng 
RY, Medvedovic M, Ho SM. Persistent hypomethylation in 
the promoter of nucleosomal binding protein 1 (Nsbp1) 
correlates with overexpression of Nsbp1 in mouse uteri 
neonatally exposed to diethylstilbestrol or genistein 
Endocrinology  2008 Dec;149(12):5922-31 
Wahafu W, He ZS, Zhang XY, Zhang CJ, Yao K, Hao H, 
Song G, He Q, Li XS, Zhou LQ. The nucleosome binding 
protein NSBP1 is highly expressed in human bladder cancer 
and promotes the proliferation and invasion of bladder 
cancer cells Tumour Biol  2011 Oct;32(5):931-9 
Wei P, Qiao B, Li Q, Han X, Zhang H, Huo Q, Sun J. 
microRNA-340 Suppresses Tumorigenic Potential of 
Prostate Cancer Cells by Targeting High-Mobility Group 
Nucleosome-Binding Domain 5 DNA Cell Biol  2016 
Jan;35(1):33-43 
Weng M, Song F, Chen J, Wu J, Qin J, Jin T, Xu J. The high-
mobility group nucleosome-binding domain 5 is highly 
expressed in breast cancer and promotes the proliferation 
and invasion of breast cancer cells Tumour Biol  2015 
Feb;36(2):959-66 
Yang C, Gao R, Wang J, Yuan W, Wang C, Zhou X. High-
mobility group nucleosome-binding domain 5 increases 
drug resistance in osteosarcoma through upregulating 
autophagy Tumour Biol  2014 Jul;35(7):6357-63 
Yao K, He L, Gan Y, Zeng Q, Dai Y, Tan J. MiR-186 
suppresses the growth and metastasis of bladder cancer by 
targeting NSBP1 Diagn Pathol  2015 Aug 20;10:146 
Zhang S, Schones DE, Malicet C, Rochman M, Zhou M, 
Foisner R, Bustin M. High mobility group protein N5 
(HMGN5) and lamina-associated polypeptide 2α (LAP2α) 
interact and reciprocally affect their genome-wide chromatin 
organization J Biol Chem  2013 Jun 21;288(25):18104-9 
Zhang XY, Guo ZQ, Ji SQ, Zhang M, Jiang N, Li XS, Zhou 
LQ. Small interfering RNA targeting HMGN5 induces 
apoptosis via modulation of a mitochondrial pathway and 
Bcl-2 family proteins in prostate cancer cells Asian J Androl  
2012 May;14(3):487-92 
Zhou LQ, Song G, He ZS, Hao JR, Na YQ. [Effects of 
inhibiting nucleosomal binding protein 1 on proliferation of 
human prostate cancer cells] Zhonghua Yi Xue Za Zhi  2007 
Feb 6;87(6):404-8 
Zhou X, Yuan B, Yuan W, Wang C, Gao R, Wang J. The 
expression and clinical significance of high mobility group 
nucleosome binding domain 5 in human osteosarcoma 
Tumour Biol  2014 Jul;35(7):6539-47 
dela Peña I, Kim HJ, Sohn A, Kim BN, Han DH, Ryu JH, 
Shin CY, Noh M, Cheong JH. Prefrontal cortical and striatal 
transcriptional responses to the reinforcing effect of 
repeated methylphenidate treatment in the spontaneously 
hypertensive rat, animal model of attention-
deficit/hyperactivity disorder (ADHD) Behav Brain Funct  
2014 May 6;10:17 
This article should be referenced as such: 
Bustin M, Furusawa T. HMGN5 (High Mobility Group 
Nucleosome binding domain 5). Atlas Genet Cytogenet 
Oncol Haematol. 2017; 21(1):Erreur ! Signet non 
défini.-6. 
 


HMGN5 (High Mobility Group Nucleosome binding domain 5)

http://documents.irevues.inist.fr/bitstream/2042/68126/1/04-2016-HMGN5ID52454chXq21.pdf

HMGN5 (High Mobility Group Nucleosome binding domain 5)

Abstract

Similar works

Full text

Available Versions

I-Revues